HC Wainwright & Co. Downgrades Outlook Therapeutics to Neutral, Announces $1 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao has downgraded Outlook Therapeutics (NASDAQ:OTLK) from Buy to Neutral and set a price target of $1.
August 31, 2023 | 10:26 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Outlook Therapeutics has been downgraded from Buy to Neutral by HC Wainwright & Co. with a new price target of $1.
The downgrade from Buy to Neutral by a prominent analyst indicates a less optimistic outlook for the company's stock. This, combined with a low price target, could negatively impact investor sentiment and potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100